Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports. They currently have a $11.00 target price on the stock. Needham & Company LLC's price target points to a potential upside of 46.86% from the company's current price.
Separately, KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th.
Get Our Latest Research Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Up 3.5 %
Shares of Recursion Pharmaceuticals stock traded up $0.25 during mid-day trading on Thursday, hitting $7.49. 24,568,288 shares of the stock were exchanged, compared to its average volume of 18,530,172. The company has a 50-day simple moving average of $7.15 and a 200 day simple moving average of $6.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business posted ($0.43) EPS. The firm's revenue was up 147.6% compared to the same quarter last year. Research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.
Insider Buying and Selling at Recursion Pharmaceuticals
In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. 15.75% of the stock is owned by company insiders.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its holdings in Recursion Pharmaceuticals by 32.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company's stock worth $837,000 after acquiring an additional 27,440 shares in the last quarter. Algert Global LLC acquired a new position in Recursion Pharmaceuticals in the second quarter worth $129,000. SG Americas Securities LLC raised its holdings in shares of Recursion Pharmaceuticals by 249.0% during the third quarter. SG Americas Securities LLC now owns 89,325 shares of the company's stock worth $589,000 after purchasing an additional 63,727 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Recursion Pharmaceuticals by 33.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company's stock worth $458,000 after buying an additional 17,400 shares during the last quarter. Finally, San Luis Wealth Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
